Events

Integrating science and action to accelerate the HIV response in Latin America

IAS – the International AIDS Society – in partnership with Evandro Chagas National Institute of Infectious Diseases at Oswaldo Cruz Foundation (INI-FIOCRUZ), is pleased t

Vaccinal effect of monoclonal antibodies: A Vaccine Enterprise timely topics roundtable

Several investigational studies of monoclonal antibodies for the prevention of infectious diseases and the treatment of cancer have shown that they are able to enhance the adaptive immune response in addition to providing protective immunity or anti-tumour activity. Various mechanisms of action have been identified, including complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular viral inhibition.

HIVR4P symposia series - The future of bNAbs

Join us this October 2023 for a virtual symposia series exploring the latest HIV prevention research.

How do you scale up use of CAB-LA and the vaginal ring? What are the latest developments in the quest for an effective HIV vaccine? What role can bNAbs play in HIV cure research? 

You're invited to attend a series of three special virtual symposia in October 2023 that will explore these questions by bringing together the scientific community to address the biggest challenges in biomedical prevention. 

HIVR4P symposia series - Insights in HIV vaccine research

Join us this October 2023 for a virtual symposia series exploring the latest HIV prevention research.

How do you scale up use of CAB-LA and the vaginal ring? What are the latest developments in the quest for an effective HIV vaccine? What role can bNAbs play in HIV cure research? 

You're invited to attend a series of three special virtual symposia in October 2023 that will explore these questions by bringing together the scientific community to address the biggest challenges in biomedical prevention. 

HIVR4P symposia series - Implementation and rolling out of CAB-LA

Join us this October 2023 for a virtual symposia series exploring the latest HIV prevention research.

How do you scale up use of CAB-LA and the vaginal ring? What are the latest developments in the quest for an effective HIV vaccine? What role can bNAbs play in HIV cure research? 

You're invited to attend a series of three special virtual symposia in October 2023 that will explore these questions by bringing together the scientific community to address the biggest challenges in biomedical prevention. 

The 12th IAS Conference on HIV Science

IAS 2023, the 12th IAS Conference on HIV Science, will take place in Brisbane, Australia, and virtually from 23 to 26 July 2023. IAS 2023, being held at the Brisbane Convention and Exhibition Centre, will shine a spotlight on the world’s advances in HIV research.

2023 HIV Cure & Immunotherapy Forum

The 2023 HIV Cure & Immunotherapy Forum, organized by the IAS Towards an HIV Cure initiative, will be held at the Brisbane Convention & Exhibition Centre in Brisbane, Australia, on 22 July 2023 alongside IAS 2023, the 12th IAS Conference on HIV Science. The content of the Forum will be accessible online after the meeting.  

Putting people first in the prevention, treatment and care of HPV-related cancers among people living with HIV

View the session recordings here.

Publish or Perish: How to write and submit a scientific manuscript

The workshop will draw on the expertise in academic publishing of the Editors of the Journal of the International AIDS Society (JIAS). It aims to build skills in scientific writing and provides practical information to support new- and early-career HIV researchers, as well as more experienced researchers, in successfully writing a scientific manuscript. By the end of the presentation, participants will know the key components of manuscript writing, how to correctly write each section, and how to avoid common pitfalls that result in the rejection of a manuscript.

Science and community in the HIV response in the Democratic Republic of Congo

Webinar: Growing older with HIV in the Treat-All Era

As access to antiretroviral therapy has improved significantly, the ageing population living with HIV has grown rapidly. UNAIDS estimates that the number of people aged 50 years or older living with HIV globally increased from 5.4 million in 2015 to 8.1 million in 2020. This means that HIV services must develop and strengthen interventions that address the evolving health needs of an ageing population beyond just HIV care.

Todos unidos en la respuesta al VIH: Ciencia, gobierno y sociedad civil

IAS – the International AIDS Society – in partnership with the Sociedad Chilena de Infectología (SOCHINF), is pleased to invite you to a scientific symposium, titled “Todos unidos en la respuesta al VIH: Ciencia, gobierno y sociedad civil”, which will be held in person in Santiago, Chile, on 27 October 2022.

Presentations will cover the following topics:

Fast-Track Cities 2022 conference

Organizers: International Association of Providers of AIDS Care (IAPAC), the Joint United Nations Programme on HIV/AIDS, Fast-Track Cities Institute, Stop TB Partnership and World Hepatitis Alliance

Building regulatory and ethics expertise for experimental medicine

There is growing interest in experimental medicine for the development of an HIV vaccine. Experimental medicine can accelerate the progress of the most pertinent HIV vaccine candidates through the development pipeline. However, these trials come with many challenges, including approval of study protocols by regulatory authorities and agencies and Ethics Review Committees.

Engaging adolescent girls and young women in HIV prevention research – Unpacking the ethical dilemmas

The second in a two-part series, it will explore how we can leverage learnings from behavioural research to enhance better engagement of adolescent girls and young women in HIV programmes and research.

Engaging adolescent girls and young women in HIV prevention research – Unpacking the ethical dilemmas

The first in a two-part series, it will explore the need for engaging adolescent girls and young women in HIV research and help understand latest scientific developments and the ethical dilemmas.

The 24th International AIDS Conference

For the first time, the world’s largest conference on HIV and AIDS will be hosted in person in Montreal, Canada, as well as virtually, to make it accessible to as many people as possible.

Pathways to an HIV cure: Research and advocacy priorities

IAS – the International AIDS Society – through its Towards an HIV Cure programme, organised the annual HIV cure meeting just before AIDS 2022, the 24th International AIDS Conference, as an Affiliated Independent Event. The hybrid meeting was organised in partnership with the Canadian HIV Cure Enterprise (CanCURE) and the FRQS - AIDS and Infectious Diseases Research Network. It took place in person at the Centre Hospitalier de l'Université de Montréal (CHUM) and virtually on 28 July 2022.

Getting to the Heart of Stigma Pre-conference

This pre-conference is a thought-leadership symposium seeking to present, discuss and interrogate the state-of-the-field evidence base for HIV-related stigma. It will be a platform to discuss global financial, strategic and programmatic efforts to contextualize, implement and scale up effective stigma reduction and mitigation interventions.

Reflections on the COVID-19 pandemic and its application to the HIV response in West and Central Africa

IAS – the International AIDS Society – and APIN Public Health Initiatives are pleased to invite you to a regional scientific symposium, “Reflections on the COVID-19 pandemic and its application to the HIV response in West and Central Africa”.

Speakers and participants will discuss the following key and pressing topics for the region:

Research priorities for an HIV cure: IAS Global Scientific Strategy

An HIV cure is a high priority for people living with HIV and an essential tool for the HIV response; a curative intervention could overcome the limitations of antiretroviral therapy (ART), limit new HIV transmissions, reduce stigma and discrimination, and provide a sustainable financial solution for epidemic control. IAS – the International AIDS Society – convened a 68-member International Scientific Working Group to develop the third Global Scientific Strategy, published in Nature Medicine in December 2021.